TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$273.7 Million

Graphite Bio, Inc.

Initial Public Offering

Bookrunner, June 2021

Graphite Bio, Inc.

Graphite Bio, Inc. is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. The Company is pioneering a precision gene editing approach to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Their next-generation gene editing platform precisely corrects mutations, replaces entire disease-causing genes with normal genes, or inserts new genes into predetermined, safe locations. Their lead product candidate GPH101 is a highly differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression.